Sanofi Research and Development Expenses 2010-2024 | SNY
Sanofi annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
- Sanofi research and development expenses for the quarter ending September 30, 2024 were $2.036B, a 12.51% increase year-over-year.
- Sanofi research and development expenses for the twelve months ending September 30, 2024 were $7.754B, a 8.5% increase year-over-year.
- Sanofi annual research and development expenses for 2023 were $7.282B, a 3.06% increase from 2022.
- Sanofi annual research and development expenses for 2022 were $7.065B, a 4.92% increase from 2021.
- Sanofi annual research and development expenses for 2021 were $6.734B, a 6.63% increase from 2020.
Sanofi Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$7,282 |
| 2022 |
$7,065 |
| 2021 |
$6,734 |
| 2020 |
$6,316 |
| 2019 |
$6,740 |
| 2018 |
$6,961 |
| 2017 |
$6,185 |
| 2016 |
$5,723 |
| 2015 |
$5,643 |
| 2014 |
$6,413 |
| 2013 |
$6,336 |
| 2012 |
$6,330 |
| 2011 |
$6,701 |
| 2010 |
$5,844 |
| 2009 |
$6,391 |
Sanofi Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-09-30 |
$2,036 |
| 2024-06-30 |
$1,835 |
| 2024-03-31 |
$1,866 |
| 2023-12-31 |
$2,017 |
| 2023-09-30 |
$1,810 |
| 2023-06-30 |
$1,777 |
| 2023-03-31 |
$1,678 |
| 2022-12-31 |
$1,882 |
| 2022-09-30 |
$1,748 |
| 2022-06-30 |
$1,764 |
| 2022-03-31 |
$1,671 |
| 2021-09-30 |
$1,702 |
| 2021-06-30 |
|
| 2021-03-31 |
$1,526 |
| 2020-09-30 |
$1,544 |
| 2020-03-31 |
$1,478 |
| 2019-09-30 |
$1,512 |
| 2019-03-31 |
$1,573 |
| 2018-03-31 |
$1,573 |
| 2017-12-31 |
$1,720 |
| 2017-09-30 |
$1,576 |
| 2017-06-30 |
$1,494 |
| 2017-03-31 |
$1,395 |
| 2016-12-31 |
$1,553 |
| 2016-09-30 |
$1,363 |
| 2016-06-30 |
$1,445 |
| 2016-03-31 |
$1,362 |
| 2015-09-30 |
$1,508 |
| 2015-06-30 |
$1,427 |
| 2014-06-30 |
$1,630 |
| 2013-06-30 |
$1,549 |
| 2012-06-30 |
$1,592 |
| 2012-03-31 |
$1,542 |
| 2011-12-31 |
$1,746 |
| 2011-09-30 |
$1,729 |
| 2011-06-30 |
$1,722 |
| 2011-03-31 |
$1,504 |
| 2010-12-31 |
$1,528 |
| 2010-09-30 |
$1,400 |
| 2010-06-30 |
$1,378 |
| 2010-03-31 |
$1,538 |
| 2009-12-31 |
$1,873 |
| 2009-09-30 |
$1,585 |
| 2009-06-30 |
$1,509 |
| 2009-03-31 |
$1,424 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$121.816B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
